Get started on Tosymra® (sumatriptan nasal spray) 10 mg with Cove


Get past your migraine pain, FAST



Tosymra® is a fast-acting prescription medicine used to treat acute migraine with or without aura in adults. It’s not for migraine prevention.

Some people experience migraine pain relief in as little as 10 minutes with one mist-like spray (13% compared to 5% for placebo). Time to onset and degree of pain relief varies by patient.

Do not take Tosymra® if you have hemiplegic migraines or basilar migraines. Do not use Tosymra if you have heart problems, narrowing of blood vessels or uncontrolled high blood pressure. These are not all the reasons not to take Tosymra.

Click here to see full Prescribing and Patient Information



Tosymra® has partnered with Cove, a telemedicine company focused entirely on migraine. Cove can connect you with an independent, licensed healthcare provider who will manage your migraine care and help determine if Tosymra® is right for you.


Eligible commercially insured patients may pay as little as $0* for Tosymra® with Cove when filled through select pharmacies. Learn more

*Restrictions and quantity limits apply. Visit to view complete program terms and conditions. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.

Why Cove's Telemedicine is Effective

Specialized Care


 Cove only treats migraine. Our program is overseen by world-leading experts in headache medicine, to ensure you get the highest quality of care from consultation to ongoing support.

Your migraine isn't on a 9-5 schedule, so neither is Cove. Message your dedicated Cove doctor day or night and they'll get back to you within 24 hours.



You are matched with a Cove doctor who follows you over time. Your doctor learns about your migraine and tailors treatment specifically to your needs.

Log your migraine in Cove’s migraine tracker, and the data will be sent to your Cove doctor to help identify your triggers to get you the relief you deserve.


  1. Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
  2. Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
  3. Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.